Abbott Laboratories

New York Stock Exchange
Back to all articles
Slightly Bullish +25

B&D White Capital Company LLC Makes New Investment in Abbott ...

AI-generated analysis

📈 B&D White Capital Company LLC acquired a new stake of 23,500 shares in Abbott Laboratories valued at approximately $2.41 million during the first quarter.

📉 Goldman Sachs lowered its price target to $113.00 while maintaining a 'buy' rating, and Stifel Nicolaus reduced its target to $120.00 with a 'buy' rating.

📈 JPMorgan Chase increased its price target to $120.00 and assigned an 'overweight' rating in a July 17th research note.

💰 Abbott Laboratories reported quarterly revenue of $12.51 billion, representing a 13% year-over-year increase compared to the prior period.

📊 The company posted earnings per share of $1.31 for the quarter, topping analyst estimates of $1.28 by $0.03.

📅 Abbott Laboratories set Q3 2026 EPS guidance between $1.38 and $1.46, with full-year 2026 guidance ranging from $5.45 to $5.60.

💵 The firm declared a quarterly dividend of $0.63 per share payable on August 17th for stockholders of record on July 15th.

👔 Director Daniel J. Starks purchased 10,000 shares at an average cost of $92.65, increasing his direct ownership by 0.15%.

📉 The stock opened at $100.69 with a market capitalization of $175.38 billion and a P/E ratio of 32.59.

🏥 Abbott operates through diagnostics, medical devices, nutritionals, and pharmaceuticals, serving hospitals, clinics, and direct-to-consumer channels.

Bullish Signals
  • Abbott Laboratories beat quarterly earnings expectations with EPS of $1.31 versus the consensus estimate of $1.28.
  • The company achieved a 13% year-over-year revenue increase to $12.51 billion, demonstrating strong top-line growth.
  • JPMorgan Chase raised its price target to $120.00 and upgraded the rating to 'overweight', signaling confidence in future performance.
  • The firm maintains a healthy balance sheet with a debt-to-equity ratio of 0.56 and a current ratio of 1.39.
  • Abbott Laboratories has a strong dividend yield of 2.5% with an annualized payout of $2.52 per share.
  • Management provided clear forward guidance for Q3 2026 EPS between $1.38 and $1.46, indicating operational stability.
Risk Factors
  • Goldman Sachs lowered its price target from $121.00 to $113.00, reflecting a more cautious near-term outlook.
  • Stifel Nicolaus decreased its price target from $145.00 to $120.00, suggesting potential headwinds or valuation concerns.
  • The stock is trading below its 200-day moving average of $101.48, indicating some short-term weakness relative to longer-term trends.
  • Equities research analysts predict a consensus EPS of $5.51 for the current year, which is slightly higher than management's upper guidance range of $5.60, implying potential pressure on expectations.
Full Analysis
Abbott Laboratories (NYSE:ABT) saw significant institutional activity in the first quarter, with B&D White Capital Company LLC acquiring a new stake of 23,500 shares valued at approximately $2.41 million. Several other smaller funds also initiated positions in the fourth quarter, while hedge fund ownership remains high at 75.18%. Director Daniel J. Starks increased his personal holdings by purchasing 10,000 shares for roughly $926,500, bringing his total direct ownership to over 6.75 million shares. Analyst sentiment regarding Abbott Laboratories is mixed but generally positive, with a consensus rating of 'Moderate Buy' and an average price target of $118.61. While Goldman Sachs, Stifel Nicolaus, and Evercore recently lowered their price targets to the $113-$120 range, JPMorgan Chase and BTIG Research raised theirs to $120 and $134 respectively. The stock currently trades around $100.69, trading below its 200-day moving average but above its 50-day average. Financially, Abbott reported strong quarterly results with revenue of $12.51 billion, slightly missing estimates by a negligible margin, and earnings per share (EPS) of $1.31, which beat the consensus of $1.28. The company posted a 13% year-over-year revenue increase, maintaining healthy margins of 11.65% and a return on equity of 17.65%. Management has provided guidance for Q3 2026 EPS between $1.38 and $1.46, with full-year 2026 targets ranging from $5.45 to $5.60.